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Abstract 
Harmonized methodologies are urgently required for the taste evaluation of novel pediatric 
medicines. This study utilized in vitro, in vivo and clinical data to evaluate the palatability of 
a novel midazolam chocolate tablet. In vitro dissolution experiments showed the crushed tablet 
to release within 5 min 1.68 mg of midazolam into simulated saliva. This translated to a drug 
level of 0.84 mg/ml in the oral cavity, which would be higher than the midazolam bitterness 
detection threshold concentration of 0.03 mg/ml determined in a rat ‘brief access taste 
aversion’ (BATA) model. The visual analogue scale scores of patients aged 4 – 16 years 
prescribed with midazolam pre-surgery showed a clear preference for the midazolam 
chocolate tablets (3.35  1.04, n = 20) compared to the control midazolam solution (1.47  
0.62, n = 17). The clinical data was in agreement with the in vivo rodent data in showing the 
novel chocolate tablet matrix to be effective at taste-masking the bitter midazolam.  
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1.0 Introduction  
In pediatric patients, the unpleasant taste of a medicine is one of the commonest causes 
of treatment barrier (1), and the importance of building palatability into pediatric medicines is 
now recognized by the pharmaceutical industry (2) and the regulatory authorities (3, 4). 
However, there is no specific regulatory framework for palatability assessment, which has 
resulted in a lack of harmonization of taste evaluation methodologies applied in the 
development of pediatric medicines (5, 6).  
The simplest taste evaluation methods for peroral pediatric medicines is to determine the 
in vitro drug release profile of the medicines in simulated physiological fluids, the rationale 
being that only the freely soluble drug molecules can interact with taste receptors. While cheap 
and readily accessible, this method is better suited to solid medicines, not solution 
formulations, and provides a measure of taste only when human perception of the tastant is 
known to some extent (e.g. as a taste threshold concentration). Currently, there are no 
regulatory-defined parameters to simulate drug release in the oral cavity from medicines. 
Published studies that have utilized the in vitro drug dissolution method to evaluate medicine 
palatability have employed a range of dissolution medium (water (7) to pH 6.8 phosphate 
buffer (8, 9)), receptor fluid volume (10 ml (10) to 900 ml (8)), and dissolution time (2 min 
(8, 9) to 5 min (7)). 
Electronic taste evaluation may be a better alternative (11) as it can profile the taste 
characteristic of the drug molecule via an array of sensors (12). Compared to in vivo models, 
electronic sensors also provide a more objective and consistent taste evaluation without 
incurring the ethical and safety concerns associated with using animal and human participants. 
Electronic tongues are, however, limited by their application to assess only aqueous solutions, 
and the sensor sensitivity can be affected by formulation pH and excipients (13).   
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An in vivo model that exploits the natural defense mechanism in most animals to avert 
bitter-tasting substances has also been developed for the palatability testing of medicines (14). 
Mildly water-deprived rats are presented with the liquid tastant, and an IC50 dose, defined as 
the tastant concentration that causes a 50% drop in licking frequency compared to water, is 
determined. This model is advocated for novel lead compounds whose toxicology has not been 
adequately elucidated to safeguard taste evaluation in humans. Products for evaluation by this 
method have to be liquid formulations of appropriate viscosity, and if they are suspensions, to 
have particles below a threshold diameter to enable the liquid formulations to flow freely 
through the sipping tube for the animals to lick. It is difficult to establish the accuracy of taste 
evaluation in animal models because the in situ drug concentration in the oral cavity cannot 
be measured accurately. Even if this concentration is measurable, it may still not correlate with 
‘palatability’ and ‘acceptable taste’ as these perceptions are dependent also on other factors, 
e.g. the age and taste receptor expression of the animal model used.   
The most direct measurement of palatability of a product is to conduct taste evaluation in 
humans, ideally in the specified pediatric age groups to account for age–related sensitivities 
towards bitter and sweet tastes (15, 16). Pediatric taste studies are, however, associated with 
significant methodological and ethical barriers around participant recruitment. Parents and 
clinicians may resist a taste trial where a healthy child may accidently ingest a 
pharmacologically active agent, especially a novel yet-to-be-approved potent agent. On the 
other hand, parents and clinicians struggling to achieve treatment compliance in a child who 
requires the intervention of an unpalatable drug may be more inclined to support a clinical trial 
to evaluate a potentially better tasting product of the drug. In such cases, however, the 
application of a cross-over study design with placebo or comparator tastant could be unethical. 
Children may also be less able than adults to describe taste, and taste trials involving children 
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may have to rely on scales of assessment that are yet to be validated for taste evaluation, e.g. 
the 5-point facial hedonic scale and visual analogue scales (6). 
Midazolam is a bitter drug that has caused considerable grief in pediatric hospitals. It is 
widely prescribed as a pre-medication aimed at calming young patients scheduled for surgery 
and dental procedures. Taste masking of midazolam has been challenging, with both the 
commercial and extemporaneously compounded oral midazolam syrups known anecdotally 
for high rejection rates due to poor taste. Rejection of the medicine presents particular 
difficulties in children who are very anxious or uncooperative in the preoperative setting, e.g. 
autistic children. In the event of treatment failure, the uncooperative children may have to be 
physically restrained for the induction of anesthesia, posing, particularly in older children, 
significant safety risks for the patients, accompanying parent/guardian and attending medical 
staff.  
Our laboratory has developed a novel chewable chocolate-based tablet containing 5 mg of 
midazolam HCl for use in children. These are small tablets measuring 10 x 5 x 5 mm with 3 
score lines to facilitate dose division (Figure 1A). The aim of this study was to provide a first-
in-kind comprehensive evaluation of the palatability of a pediatric dosage form using a range 
of methodologies and the midazolam chocolate tablet as a model formulation. We applied the 
in vitro dissolution test, the rat brief-access taste aversion (BATA) model and a clinical trial 
involving patients aged 4 – 16 years of age to the taste evaluation of the chewable midazolam 
chocolate tablet. The electronic tongue was excluded because it would involve conducting a 
dissolution experiment for the midazolam chocolate tablets and analyzing filtered aliquots of 
the dissolution medium in the E-tongue. The filtered aliquots would not provide an accurate 
measure of the effectiveness of the chocolate matrix in masking the taste of the released drug. 
In this regard, the E-tongue would not offer significant advantages to the dissolution 
experiments in evaluating the taste of the formulation. A correlation of the in vitro dissolution 
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profile, animal taste aversion profile and pediatric taste scores for the chewable tablet, together 
with issues associated with each of the methodologies, is discussed in the present study.  
 
2.0 Materials and Methods 
Midazolam hydrochloride (HCl) (BP grade, Cambrex Profarmaco Milano, Italy) was used as 
received. All other chemicals were of analytical grade. Deionized water (PSI Water Filters, 
Launceston, TAS, Australia) was used throughout. 
 
2.1 Preparation and storage stability of chocolate-based chewable tablets 
 Chewable tablets each containing 5 mg of midazolam hydrochloride and measuring 
10x5x5 mm were prepared by a melt moulding technique using generally regarded as safe 
excipients that included dark chocolate (Nestle Australia Ltd, Rhodes, NSW, Australia), 
hydrogenated castor oil, xanthum gum, polyethylene glycol 1450, and steviol glycosides. All 
ingredients, except for the dark chocolate, were of pharmaceutical grades (BP or USP) and 
obtained from registered pharmaceutical suppliers in Australia. 
 
2.2 In vitro drug dissolution profiles 
In vitro drug dissolution was conducted in triplicates using a paddle rotating speed of 50 
rpm (Varian VK 7010 Dissolution Apparatus, Agilent Technologies, Mulgrave, Victoria, 
Australia). Tablets weighed into separate porcelain crucibles were ‘masticated’ by crushing 
with a glass rod into small fragments (Figure 1B), and placed into 300 ml of simulated saliva 
(8 mg/ml sodium chloride, 0.19 mg/ml potassium phosphate monobasic, 2.38 mg/ml sodium 
phosphate dibasic, pH 6.8) (17) at 37 C. One-ml aliquots were sampled at 0, 5, 15, 30, 45 and 
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60 min, and simultaneously replaced with 1 ml of blank dissolution medium. The aliquots 
were filtered (Fitropur S 0.2 µm filter, Sarstedt Australia Pty. Ltd, Adelaide, SA, Australia), 
diluted 1:1 v/v with blank dissolution medium, and analyzed by a validated high performance 
liquid chromatographic (HPLC) assay. Parallel experiments were conducted under sink 
conditions using 500 ml of 0.1M HCl as dissolution medium. Withdrawn aliquot samples were 
filtered, mixed 1:1 v/v with methanol and analyzed by HPLC. A third dissolution profile was 
obtained of intact tablets in 500 ml of 0.1M HCl. The cumulative amounts of drug released, 
expressed as a percent of initial drug load in the tablet, were plotted against sampling times to 
obtain the in vitro dissolution profiles.  
Midazolam HCl was quantified by reversed-phase HPLC (Agilent 1260 Infinity binary 
pump HPLC, Agilent Technologies Australia, Mulgrave, NSW, Australia) with a C18 column 
(3.5 m, 100 x 3.0 mm) (Sunfire, Waters Australia Pty Ltd, Rydalmere, NSW, Australia). 
Gradient elution at flow rate of 0.45 mL/min was employed. The mobile phase of 25% v/v 
acetonitrile (ACN) and 75% v/v potassium phosphate buffer (20 mM phosphate, pH 3.8) was 
graded to 100% ACN in 6 min, then held isocratic for the next 6 min. Midazolam was detected 
at 237 nm. Linearity of calibration graphs (R2 > 0.99) was demonstrated over the concentration 
ranges of 0.04 to 25 μg/ml and 0.5 to 20 μg/ml for the standard solutions of midazolam HCl 
in 0.1 M HCl and simulated saliva (pH 6.8), respectively.  
 
2.3 In vivo rat taste aversion profile 
Ten male Sprague Dawley rats (average weight 719  126 g) previously trained for the 
rat BATA experiments (18) were used for two independent tasting evaluations. Animal 
procedures were carried out in accordance with the UK Animals (Scientific Procedures) Act 
1986 (Project License PPL 70/7668). 
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Prior to experiments, the rats were mildly deprived of water for 22 hours but had access 
to food ad libitum.  Taste evaluation was performed in consecutive 40-min sessions using one 
rat at a time. The rat was placed into a Lickometer Davis Rig MS-160 (DiLog Instruments, 
Tallahassee, Florida, USA) apparatus that held 16 sample tubes on a moving rack controlled 
by the Davis Collect Data software. Each tube was presented to the rat via a sipper tube for 8 
s, in randomized order specified by the software. Over the 40-minute session, each sample 
was presented to the rat 4 times, with a 2-s deionized water rinse given between samples. The 
number of licks received for a tube was transmitted and recorded electronically onto a 
database.   
The midazolam chocolate tablet was assessed against 5 controls - water, vehicle (water 
adjusted to pH 5 with HCl), 1 mg/mL solution of midazolam HCl in the vehicle, 2.5 mg/mL 
oral midazolam HCl syrup (a proprietary formulation manufactured by the WA Hospital 
Central Pharmaceutical Manufacturing Facility, Princess Margaret Hospital, Perth, Australia) 
and chocolate placebo tablets. The placebo and midazolam-loaded chocolate tablets were 
triturated in the vehicle (2 mL per tablet, mimicking a realistic volume of saliva) using a mortar 
and pestle to allow passage through the sipper tubes without blockage. Calibration of 
midazolam taste threshold was also performed with standard solutions of midazolam HCl 
dissolved in the vehicle at 6 concentrations (range of 0.003 to 1 mg/mL).   
 
2.4 Clinical taste evaluation in pediatric patients 
Taste evaluation was conducted in a prospective, open-label, single center, randomized, 
single-treatment trial involving children aged 4 – 16 years undergoing elective surgery and 
who had been prescribed midazolam for pre-medication by an anesthetist independent of the 
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study team at the Princess Margaret Hospital. The study was approved by the hospital Human 
Research Ethics Committee (HREC 2014102EP; anzctr.org.au: ACTRN12615000225516).  
All participants were recruited on the day of their surgery. Written informed parental 
consent and, where appropriate, child assent were sought prior to inclusion into the study 
protocol. Each child was randomized by computer generated block randomization to receive 
by mouth either the chocolate-based midazolam tablet or a 5 mg/ml midazolam IV solution, 
which was the preferred mode of midazolam administration at the hospital. Participants in the 
chocolate tablet arm were instructed to chew the tablet before swallowing. Midazolam was 
dosed at 0.5 mg/kg to a maximum of 20 mg, but the treating anesthetists were free to change 
the dose according to the clinical need. Children in the study received doses of 6.25 to 20 mg, 
equivalent to 1¼ to 4 midazolam chocolate tablets, or 1.25 to 4 ml of midazolam solution. 
After the child had taken the allocated midazolam sample, a trained research nurse would 
record on a five-point facial hedonic scale (Figure 2) whether the child liked the taste of the 
medication or not. Non-invasive pharmacodynamic data (time to onset of sedation) was also 
collected for each patient to determine the clinical effect of midazolam. The child patient was 
asked to record how much he/she liked the sample by putting a mark on a separate five-point 
facial hedonic scale, and whether he/she would be happy to take the sample again if unwell. 
The attending parent/guardian was also asked to give a score on a third five-point hedonic 
scale on how he/she perceived the child’s response to the taste of the assigned medication.   
 
2.5 Statistical analysis 
Rat aversion data were analyzed using the R statistical software (http://www.R-
project.org) after removal of data sets with  1 lick (19), and the comparison of means was 
performed using 2-tailed unpaired t-test. Non-parametric Mann-Whitney test and 2-tailed 
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unpaired t-test were applied on the clinical taste evaluation data. With the effect size d=1.0 
and α=0.05, this trial has 80% power to detect a difference with 18 children in each group 
(G*Power 3.1). The gender distribution and the participant’s willingness to take the second 
dose were analyzed using 2-tailed Chi-square test. All statistical analyses were performed with 
PRISM 6 for Mac (GraphPad software). A P value <0.05 was considered statistically 
significant. 
 
3.0 Results 
HPLC analysis of the tablets immediately after manufacture showed a midazolam 
hydrochloride content of 5.12 ± 0.16 mg/tablet (n = 3). The tablets were stable for at least 18 
months when stored at ambient temperature. Residual midazolam content at 12 and 18 months 
of storage were 96.84 ± 4.18% and 91.00 ± 0.01 % (n = 3), respectively. 
There was complete release (99.52  3.22%, n = 3) of the midazolam HCl load from the 
masticated 5 mg tablets after 15 min in the 0.1 M HCl medium (Figure 3). The absence of 
extraneous peaks, and the complete release of intact drug suggests a lack of interaction 
between midazolam and the chocolate tablet matrix. At the zero time point, the drug already 
available from these tablets amounted to 0.62  0.70 mg, equivalent to 14.26  16.18% of the 
drug load in the tablets. Our data suggest that the pre-crushing of tablet led to faster drug 
release in the first 5 min compared with the intact tablet, the cumulative drug released differing 
by 0.62 mg at t=0 and 1.79 mg at t=5 min. If the tablets had not been crushed prior to exposure 
to the dissolution medium, the mean cumulative drug released at t=0 and t=15 min were 1.25 
 0.47% and 62.78  4.87%, respectively. The full drug load (~100%) was released from the 
intact tablets at about 35 min (Figure 3). Changing the dissolution medium for the crushed 
tablets from 0.1M HCl to simulated saliva (pH 6.8) significantly inhibited the rate of drug 
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released. The cumulative drug released reached a plateau value of about 45% (6.46 g/mL) at 
10 min, and this level was maintained over the duration of the experiment (Figure 3). 
Rat aversion to the taste of midazolam was indicated by a significant reduction in the 
number of licks when a sample was presented to the rat. Standard solutions containing up to 
0.03 mg/mL midazolam HCl received comparable licking frequencies compared to the blank 
vehicle (water adjusted to pH 5 with HCl to facilitate dissolution of midazolam HCl) (Figure 
4A). This suggests that the rats were unable to effectively detect the bitter drug presented at 
up to these concentrations. There was a significant drop in licking frequency when the drug 
concentration was increased to 0.1 mg/mL, and near abandonment of licking when the drug 
concentration was increased further to 1.0 mg/mL. Dose-response curve for the midazolam 
HCl standard solutions over the two test days suggests a mean IC50 value of 0.30  0.29 mg/mL 
(Figure 4A). There was no significant difference in the number of licks received between the 
vehicle and water. 
Figure 4B shows that, compared to the standard 1 mg/mL midazolam HCl solution, the 
liquid midazolam chocolate sample prepared by triturating the 5 mg midazolam chocolate 
tablet in 2 mL of water was significantly better received by the rats. This is despite the 
chocolate sample having a 2.5 fold higher midazolam HCl content than the standard solution. 
The mean licking frequencies for the midazolam chocolate sample and placebo chocolate 
sample were comparable, suggesting that the rats were unable to detect the bitter drug when it 
was presented in the novel chocolate tablet matrix formulated by our laboratory. In contrast, 
the proprietary oral syrup prepared by the local hospital, which also contained 2.5 mg/mL 
midazolam HCl, was less well received.  
Preliminary analysis of the clinical study was conducted based on data collected from 38 
children aged between 4 to16 years (Table 1). The data was not stratified for patient age due 
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to the small sample size. There were no significant differences in the demographic 
characteristics of participants in the midazolam chocolate tablet group and the control arm, 
which received the IV midazolam solution orally.  
Non-parametric Mann-Whitney test and 2-tailed unpaired t-test were applied on the 
clinical taste scores and both tests yielded the same outcome. There was a clear preference for 
the novel midazolam chocolate tablets (n = 20) compared to the IV midazolam solution 
administered orally (n = 17; one child in this group was too drowsy to give a score). The largest 
mean score difference between the chocolate and comparator samples was provided by the 
child participants (Figure 5). When asked whether they would take the medicine again, 75% 
of participants (n=15) in the midazolam chocolate tablet arm replied in the affirmative while 
only 35.3% of participants (n=6) in the midazolam solution arm would take the dose again 
(P=0.015). Time to onset of sedation (clinical effect of midazolam) was 11.30  5.03 min for 
the midazolam solution group and 12.40  6.39 min for the chocolate group (P > 0.05).  
 
4.0 Discussion 
Of the 3 taste evaluation studies conducted for the novel midazolam chocolate tablets, the 
simplest and cheapest to perform were the in vitro dissolution experiments. There were no 
requirements for ethics approval and animal/patient recruitment, and consistent data were 
readily obtained within days. However, the lack of consensual dissolution methodology and 
simulated salivary fluid to employ (20) has significant implications on a drug with pH-
dependent aqueous solubility. Midazolam is a weak base (pKa 6.04) (21). It is soluble in 
acidified water (>2.5 mg/ml), but the solubility decreased to < 0.1 mg/ml at pH > 5. In our 
study, the volumes of dissolution media employed were significantly higher than the volume 
of saliva in the oral cavity. This is to ensure the dissolution experiments could be optimally 
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conducted with the chocolate tablets in the USP dissolution apparatus. Despite the high 
volume of dissolution media used, drug saturation was apparent within 10 min of introducing 
the midazolam chocolate tablet into the simulated saliva (pH 6.8). This could underestimate 
drug release in the oral cavity in vivo.  Conversely, the relative ease with which midazolam 
HCl dissolved in 500 ml of 0.1 M HCl would overestimate the oral drug level. The typical 
saliva volume in human is no more than 2 ml (22), but this low volume was difficult to apply 
in dissolution experiments for the chocolate-based tablets as it rendered the samples too thick 
to be filtered for HPLC analysis. The chewable midazolam chocolate tablets are not likely to 
remain in the mouth of patients for longer than 5 min, so the extent of drug released from the 
tablet into the oral cavity can be predictable from the drug concentrations in the 0 and 5 min 
aliquot samples. In this study, the sampling time for the dissolution experiments was extended 
to 60 min to also provide us with an estimate of the peroral drug bioavailability in vivo. There 
is no validated method to simulate tablet mastication for in vitro drug dissolution studies. In 
the absence of a defined method, we have improvised a reproducible, if rather crude, method 
for the chewable chocolate tablets. However, the dissolution data could not be directly 
correlated to taste aversion without prior knowledge of the taste detection and tolerance 
thresholds for midazolam in the pediatric patients.  
Taste evaluation using the rodent BATA model allowed the test product to be 
simultaneously evaluated against a range of controls, and provided the in vivo IC50 and taste 
thresholds for midazolam HCl. On the basis that taste aversion was reflected by a significant 
reduction in the licking frequency, the detection threshold for the bitter taste of midazolam 
HCl would be about 30 g/ml in the rodent model.  
Challenges associated with the rodent model included the requirement for animal ethics 
approval. Rats had to be purchased and trained and, while the trained rats could be re-used 
over several months, there were on-going agistment costs. Another disadvantage was the 
14 
inability to administer the solid tablet to the rats with the present lickometer. Instead, the tablet 
had to be rendered into a liquid, and the concentration of midazolam presented to the rats’ oral 
cavity (2.5 mg/ml) could be higher than if the rats were administered with the chewable tablets. 
Animal behavior was also not always predictable. Despite the controlled experimental 
environment of dim lighting and minimal noise, some rats did become distracted and stop 
licking the sample presented. A waiting time to first lick of 20 seconds was imposed, and 
where a sample attracted 0 or 1 lick, whether or not this was due to the rats being distracted or 
the sample having an unpalatable taste, the data had to be discounted as outliers (possible false 
negatives) for the final data analysis. To enhance the reliability of data, 10 rats were used and 
every tastant presented 4 times, resulting in an experiment that took 7h to complete, 
discounting sample preparation time. There was no scope for automation, unlike the 
dissolution experiment, although replicate experiments could still be completed within days. 
An excellent analysis of the difficulties and precision associated with the BATA method has 
earlier been reported by our colleagues (18).   
Of the 3 studies conducted, the most direct taste data was obtained from the clinical trial, 
which also provided an analysis of pharmacodynamic effects in the target pediatric patients. 
The facial hedonic scales provided by the children suggested that the chocolate formulation 
was able to significantly mask the bitter taste of midazolam, as was the finding that 75% of 
the participants in the test group were willing to take the chocolate tablets again. The facial 
hedonic scores also suggest that the children were more willing to differentiate between the 
tastes of the midazolam chocolate tablet and solution compared to their caregivers.  
The clinical study was, however, the most expensive to conduct, and it took the longest 
time. Preclinical in vitro dissolution and animal taste data were required by the hospital ethics 
committee, and participation was restricted to patients prescribed with midazolam for pre-
surgery sedation. This then exposed the study to the unique dynamics between sick children 
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and their caregivers. For example, a child attempting to exert some control over their condition 
might refuse a medication or rate it poorly; we had children giving a low score for the 
midazolam chocolate tablet who had then asked whether they could have a second tablet. We 
also had a small number of very young children who had insisted on scores based on preferred 
facial expression on the hedonic scale rather than the taste of the medication. These factors 
underscore the urgency of validating scoring tools, including the 5-point hedonic scale used 
in this study, for the taste assessment of pediatric medicines. 
A cross-over study design that could have provided more robust comparative taste data 
was also not possible when the participants required only 1 dose of midazolam prior to surgery. 
In addition, the midazolam doses, which were prescribed by attending anesthetists 
independent of the study, did not always conform to the recommended study dose of 0.5 
mg/kg. However, even if the recommended dose had been uniformly prescribed, the 
participants, whose body weights ranged from 15.6 to 72.4 kg, would still not receive the same 
number of tablet or volume of solution. This discrepancy might affect the taste perception 
scores, but there are no industry guidelines on how to normalize the taste scores of participants 
receiving different doses of a medicine.  
The clinical taste data for the midazolam chocolate tablets correlated well with the rodent 
BATA data in showing the chocolate matrix was effective at masking the bitter taste of 
midazolam. The tablets were presented to the rats in a liquid form at a drug concentration of 
2.5 mg/ml. Despite the concentration being 83 fold higher than the detection threshold of 0.03 
mg/ml, the rats were unable to differentiate the taste of the midazolam chocolate liquid from 
the placebo chocolate liquid. In the clinical trial, the participants were instructed to chew the 
tablets prior to swallowing. The in vitro dissolution data for a crushed tablet showed 1.68 mg 
and 3.03 mg of midazolam HCl was released at 5 min into the simulated saliva (non-sink 
condition) and 0.1M HCl (sink condition) media, respectively. Taking the saliva volume to be 
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2 ml, the chewing of one midazolam chocolate tablet might therefore produce drug levels of 
0.84 – 1.52 mg/ml in the oral cavity. Higher cumulative concentrations are expected for the 
trial participants as they had received 1¼ to 4 tablets. Despite this, the pediatric participants 
had given relatively favorable taste scores for the midazolam chocolate tablets.  
Corresponding data for the midazolam solution was less correlative. This solution was a 
commercial IV midazolam injection without any taste masking agents. Its composition was 
similar to that of the midazolam standard solutions used in the rodent experiments. However, 
while the rats were clearly averse to sipping midazolam solutions stronger than 0.03 mg/ml, a 
significant number of the children were able to take the full dose (1.25 to 4 ml) of the 5 mg/ml 
midazolam solution. The administration of the solution via an oral syringe by the child 
participant or attending parent under the supervision of the research nurse might have made 
the solution more tolerable. However, it could also reflect a higher threshold tolerance for 
bitter taste in human than in rat, and/or importantly, the willingness of sick children to take 
medicines as a matter of routine regardless of the taste of the medicine. 
The novel midazolam chocolate tablet was developed following feedback from clinicians 
about the high rejection rates amongst paediatric patients administered with the commercial 
and extemporaneously prepared peroral midazolam syrups. The bitter taste of midazolam 
hydrochloride is notoriously difficult to mask in liquid products; a recent study involving 45 
paediatric patients aged 1-6 years old recorded a mean score of 3 (range 2-3 for ‘Really Bad’ 
to ‘Bad’) on a 7-point hedonic scale for a commercial midazolam syrup (23).  
The collective in vivo taste data of this study suggest that the novel chocolate-based matrix 
formulation has the potential to provide an acceptable peroral midazolam product for 
paediatric (and dysphagic) patients. Chocolate is an important taste masking ingredient, but 
the matrix also employs other ingredients to enhance its taste masking capacity, and to provide 
storage stability at ambient temperature. The generic applicability of this chewable matrix to 
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formulate acceptable products of other bitter drugs is currently being investigated in our 
laboratory.  
 
5.0 Conclusion 
Harmonized methodologies are urgently required for the taste evaluation and 
development of novel pediatric medicines. In vitro dissolution data can be rapidly and 
routinely generated to evaluate the effectiveness of taste masked medicinal products provided 
the in vivo taste threshold and tolerance concentrations of the drug are known. The latter may 
be determined using rodent taste aversion studies, which can also provide preliminary taste 
evaluation of the products in vivo. Ultimately, clinical studies involving the target pediatric 
patient population are required to validate whether the product has been effective in masking 
the aversive taste of a drug. For the midazolam chocolate tablets, the in vivo and clinical data 
concur in indicating that the novel chocolate tablet matrix was effective at taste-masking the 
unpalatable midazolam. 
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Figure Legends 
Figure 1 The midazolam chocolate tablet (A) Intact tablet; (B) Crushed tablet for in vitro 
dissolution studies. 
Figure 2  The five-point facial hedonic scale used in the clinical taste evaluation study. 
Figure 3 In vitro drug release profile from the midazolam chocolate tablet into simulated 
dissolution media at 37C; (a) ▲- whole tablet in 500 ml of 0.1 M HCl; (b)  - 
masticated tablet in 500 ml of 0.1 M HCl; and (c) - masticated tablet in 300 ml 
of simulated saliva, pH 6.8. Data represent mean  SD, n = 3. 
Figure 4 Response of Sprague Dawley rats (n = 10, data represent the sum of 2 independent 
experiments conducted over 2 days, mean with 95% confidence interval) to the 
taste of different samples (A) midazolam standard solutions prepared by 
dissolving midazolam HCl in the vehicle, * P<0.0001 compared to blank vehicle; 
and (B) test samples comprising deionized water; vehicle; dark chocolate placebo 
(500 mg dissolved in 2 mL of water); 2.5 mg/mL midazolam oral syrup; and 5 mg 
midazolam HCl chocolate tablet dissolved in 2 mL of water to give a chocolate 
liquid containing 2.5 mg/mL midazolam. Statistical significance is indicated by * 
P<0.05.  
Figure 5 Box and whisker plots (10th -90th percentile) of visual analogue scale data for the 
taste evaluation of the midazolam chocolate tablets (☐) administered orally. The 
comparator was a commercial IV midazolam solution () administered orally at 
comparable doses, which was the current practice at the Princess Margaret 
Hospital for Children. Statistical significance is indicated by *P < 0.05, **P < 
0.001, or ***P < 0.0001. 
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